Diabetes shot boosts motor function for patients with Parkinson's
A placebo trial shows that the diabetes drug exenatide improved motor symptoms of Parkinson's disease and may have disease-altering potential. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - August 4, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news
Diabetes Drug, Exenatide, Shows Promise Against Parkinson's
FRIDAY, Aug. 4, 2017 -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson ' s disease, a new study suggests. " This is a very promising finding, as the drug holds potential to affect the course of the disease itself,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 4, 2017 Category: General Medicine Source Type: news
Diabetes Drug Shows Promise Against Parkinson's
FRIDAY, Aug. 4, 2017 -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson ' s disease, a new study suggests. " This is a very promising finding, as the drug holds potential to affect the course of the disease itself,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 4, 2017 Category: General Medicine Source Type: news
Diabetes drug could help those living with Parkinson's disease
A study published inThe Lancet suggests that exenatide improves movement-related issues and might also slow the progression of the disease.The Guardian (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 4, 2017 Category: Endocrinology Source Type: news
Diabetes drug could help those living with Parkinson's disease, research reveals
Study suggests that exenatide, currently used to treat type 2 diabetes, improves movement-related issues and might also slow the progression of the diseaseA drug commonly used to treat diabetes could help those living with Parkinson ’s disease, research has revealed.By 2020 it is predicted that 162,000 individuals in the UK will be living with the condition. While existing drugs help to controlits symptoms, there are currently none available which slow or halt its progression.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 4, 2017 Category: Science Authors: Nicola Davis Tags: Medical research Parkinson's disease Diabetes Health Society Science Source Type: news
Diabetes drug could halt Parkinson's progression
Optimistic researchers say exenatide presents 'major new avenue for investigation' Related items fromOnMedica Many people ashamed to admit to Parkinson ’s disease Diabetes drug could protect against Parkinson ’s disease Hepatitis may increase risk of Parkinson's disease (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 4, 2017 Category: UK Health Source Type: news
Type 2 diabetes drug could combat Parkinson's
People with Parkinson ’s who took Exenatide – an existing diabetes medication - for around a year had better motor skills than those who took a placebo. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2017 Category: Consumer Health News Source Type: news
Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety. The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), found that people with Parkinson's who injected themselves each week with exenatide for one year performed better in movement (motor) tests than those who injected a placebo. (Source: World Pharma News)
Source: World Pharma News - August 3, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bydureon (Exenatide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 20, 2017 Category: Drugs & Pharmacology Source Type: news
MassDevice.com +5 | The top 5 medtech stories for June 14, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch ofits HAART 300 aortic annulop...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Delpor wins $1.5m NIH grant for diabetes drug implant
Delpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant.
The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide for at least 3 months.
Get the full story at our sister site, Drug Delivery Business News.
The post Delpor wins $1.5m NIH grant for diabetes drug implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Implants Pharmaceuticals delpor National Institutes of Health (NIH) Source Type: news
Delpor Awarded $1.5 million NIH Grant for Exenatide Implant for the...
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through...(PRWeb June 14, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14423867.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2017 Category: Pharmaceuticals Source Type: news
Fewer T2D Patients Advanced Therapy With GLP-1 Pump
(MedPage Today) -- Less need for additional drugs with implantable exenatide versus sitagliptin, placebo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 12, 2017 Category: Primary Care Source Type: news
EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes
Top-line results from the CV outcomes trial of once-weekly GLP-1 agonist, exenatide for diabetes show there ' s no indication of any CV harm, but there ' s also no benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
